Sanford Burnham
  • Sanford Burnham
  • Twitter
  • Facebook
  • Youtube
  • Navigate Sanford-Burnham
    • Main Site
    • Our Mission
    • Research
    • Talent
    • Technology
    • Training & Education
    • Our Supporters
    • News

Beaker

Sanford-Burnham Science Blog

Subscribe

Debunking two myths about California’s Proposition 29

by Heather Buschman, Ph.D. on April 26, 2012 at 2:04 pm | 1 comment
CCRA

The goal of Proposition 29 (the California Cancer Research Act) is to provide funding for cancer research in California by increasing the tax on a pack of cigarettes by $1. We’d like to take this opportunity to clarify two myths that opponents, including Big Tobacco, are spreading about this initiative:

Revenue generated by Prop 29 will stay in California. Section 2 of Prop 29 clearly states that the initiative’s purpose is to fund: (1) grants and loans for biomedical, epidemiological, behavioral, health services, and other research in California, (2) creation, staffing and equipping of California research facilities engaged in biomedical, epidemiological, behavioral, health services, and (3) increased efforts to reduce tobacco use in the State.

Scientists and patient advocates, not politicians, will oversee research funding generated by Prop 29. In Section 3 (page 6), Prop 29 proposes to create the HOPE 2010 Cancer Research Citizens Oversight Committee, which will establish a process for and make final decisions on soliciting, reviewing, and awarding grants and loans for research, facilities, and patient treatment. The committee will consist of nine members: (1) one member affiliated with a California Academic Medical Center; (2) three members selected from among the Cancer Center Directors of National Cancer Institute-designated cancer centers located within the State of California; (3) the Chancellor from each of the campuses of the University of California that is a member of the California Institute for Quantitative Biological Research; (4) two members appointed by the Director of the California Department of Public Health, the appointments to be selected from among California representatives of California or national disease advocacy groups whose focus is tobacco-related illness, at least one of whom shall be a person who has been treated for a tobacco-related illness.

The first two types of committee members listed above will be appointed by California’s governor, but they are not politicians or lobbyists. In fact, Section 3 of Prop 29 goes on to say that, “No person who is required to register as a lobbyist under the provisions of any law of the United States, the State of California or any local government, is eligible for appointment to the Committee.”

The full text of Proposition 29: the California Cancer Research Act can be viewed here.

 

Tags: CCRA

Post a Comment Cancel reply

* All fields are required

CAPTCHA Image
Refresh Image

*

1 Comment

  1. KG says:
    May 3, 2012 at 9:29 am

    Big tobacco loses if 29 goes through; no wonder they’ve decided to just overtly lie about it on TV.

    Reply

Search

Find more information

  • About Beaker
  • Contact us
  • Donate

Please take a quick survey

Which of these items describes you?

Select all that apply. (Question 1 of 5)

Categories

  • Basic Research
  • Cancer
    • Apoptosis & Cell Death Research
    • Signal Transduction
    • Tumor Development
    • Tumor Microenvironment
  • Children's Health
    • Genetic Diseases
    • Muscle Development & Regeneration
    • RNA Biology
  • Diabetes & Obesity
    • Cardiovascular Pathobiology
    • Metabolic Signaling & Disease
  • Drug Discovery
  • Events
  • Graduate School of Biomedical Sciences
  • Grants
  • Infectious & Inflammatory Diseases
    • Bioinformatics & Systems Biology
    • Infectious Diseases
    • Inflammatory Diseases
  • Nanomedicine
  • Neuroscience, Aging, & Stem Cells
    • Degenerative Diseases
    • Development & Aging
    • Stem Cells
  • Other
  • People
  • Sanford-Burnham Supporters
  • Translational Medicine

Search by Keyword

CCRA CIRM collaboration commitment communication community Daniel Kelly Erkki Ruoslahti Evan Snyder events Florida Hospital Fred Levine Genetic Disease Program Guy Salvesen Hudson Freeze John Reed Kristiina Vuori La Jolla Lake Nona Metabolic Signaling metabolism NIH Orlando personalized medicine Prebys Center press proteins Rare Diseases Rare disease symposium research publications Robert Wechsler-Reya Santa Barbara Sara Courtneidge Sheila Collins Stem Cells Steven Smith Stuart Lipton T. Denny Sanford technology Translational Research Institute tumor microenvironment Tumor Microenvironment Program Video Yu Yamaguchi Ze'ev Ronai

© Sanford-Burnham Medical Research Institute. All rights reserved.

Get Cloud PHP Hosting on CatN